Search Our Trials
We are currently enrolling patients in the Clinical Trials listed below. New trials open regularly, and availability is subject to change. Search using key terms to find trials for which you may be eligible. If your tumor type is not listed, please search for “Solid Tumor”.
We are here to answer your questions and guide you through this process with HOPE and compassion for your unique journey.
- C: (972) 566-3082 E: Referral@MaryCrowley.org
Search Results
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-35
AMT-116 is a ADC targeting CD44v9 with topoisomerase 1 payload.
Antibody Drug Conjugate
Solid Tumor
24-32
BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
Molecular Targeted Therapy
Bile Duct Cancer (Cholangiocarcinoma), Breast, Breast Cancer, Cervical Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Solid Tumor, Urothelial Cancer, Uterine Cancer
24-30
VET3-TGI is an attenuated, recombinant vaccinia virus designed to deliver the transgenes IL-12 and TGF-β inhibitor
Viral
No
Solid Tumor
24-26
CT7439 is a CDK12/13 inhibitor
Molecular Targeted Therapy
Solid Tumor
24-25
STP938 is a CTPS1 inhibitor
Molecular Targeted Therapy
Solid Tumor
24-22
TTX-MC138 is a modular, iron oxide nanoparticle-based nanocarrier platform (TTX) coupled to an antagomir against miR-10b
Molecular Targeted Therapy
Solid Tumor
24-20
BGB-24714 is a SMAC mimetic
Molecular Targeted Therapy
Yes
Solid Tumor
24-16
SW-682 is a TEAD inhibitor
Molecular Targeted Therapy
NF2 or other Hippo pathway mutations
Mesothelioma, Solid Tumor
24-10
APL-5125 is a CK2α inhibitor
Molecular Targeted Therapy
Appendiceal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy
KRASG12C
Lung Cancer (NSCLC), Solid Tumor
Yes
24-07
IAM1363 is a HER2 inhibitor
Molecular Targeted Therapy
Solid Tumor
24-05
BG-68501 is a CDK2 Inhibitor
Molecular Targeted Therapy
Solid Tumor
24-03
AMG 193 is a PRMT5 inhibitor
Molecular Targeted Therapy
Solid Tumor
23-30
Western Reserve vaccinia virus that expresses CCR2 and leptin-IL2.
Viral
Colorectal Cancer, Gastric/GEJ Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Skin Cancer/ Melanoma, Solid Tumor
23-29
REC-4881 is a MEK inhibitor
Molecular Targeted Therapy
Colorectal Cancer, Solid Tumor
23-28
AT-1965 is a CMTR2 inhibitor
Molecular Targeted Therapy
Not Required
Solid Tumor
23-24
FB849 is a HPK1 inhibitor
Immunotherapy
Not Required
Breast Cancer, Colorectal Cancer, Solid Tumor
23-22
GSK4524101 is a POLQ inhibitor
Molecular Targeted Therapy
Not Required
Solid Tumor
Yes
23-21
TORL-3-600 is a CDH(/cadherin)17 targeting ADC
Antibody Drug Conjugate
Not Required
Colorectal Cancer, Solid Tumor
23-19
RMC-9805 is a KRAS G12D inhibitor
Molecular Targeted Therapy
KRASG12D
Lung Cancer (NSCLC), Solid Tumor
23-18
LCB84 is an anti-TROP2 ADC
Antibody Drug Conjugate, Immunotherapy, Molecular Targeted Therapy
Anal Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
23-17
EGFR x HER3 bispecific antibody-drug conjugate
Antibody Drug Conjugate
Not Required
Lung Cancer (NSCLC), Solid Tumor
23-15
HF158K1 is a HER2-targeting antibody liposome
Antibody Drug Conjugate
HER-2 positive or HER-2 low expression
Solid Tumor
23-10
ART6043 is a Polθ inhibitor
Molecular Targeted Therapy
*Genetic lesions known to cause loss of function of known DDR genes *Hormone-receptor status, breast cancer gene (BRCA) mutation
Solid Tumor
23-09
EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
Antibody Drug Conjugate
CLDN18.2
Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
23-06
STX-478 is a PI3Kα small molecule inhibitor.
Molecular Targeted Therapy
PI3Kα
Breast Cancer, Solid Tumor
Yes
23-05
KT-253 is an MDM2 degrader
Molecular Targeted Therapy
Not Required
Lymphoma, Solid Tumor
Yes
23-01
RO7623066 is a potent, selective small molecule inhibitor of USP1 that is being developed for the treatment of solid tumors.
Molecular Targeted Therapy
Monotherapy – Tumor Biopsy Cohort: have the following deleterious homologous recombination repair (HRR+) tumor mutations: BRCA1, BRCA2, PALB2, RAD51, RAD51B, RAD51C, RAD51D, BARD1, BRIP1, FANCA,...
Solid Tumor
Yes
22-39
JAB-2485 is a small molecule Aurora A inhibitor. Inhibition of Aurora A activity at the cellular level induces apoptosis and inhibits tumor growth.
Molecular Targeted Therapy
Not Required
Breast Cancer, Lung Cancer (SCLC), Solid Tumor
Yes
22-37
ATRN-119 selectively targets and binds to ATR, and inhibits its activity and ATR-mediated signaling. This blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint...
Molecular Targeted Therapy
DNA damage response (DDR) mutations
Solid Tumor
22-36
E7386 inhibits beta-catenin and prevents the interaction of beta-catenin with its transcriptional coactivator, CREB (cAMP response element-binding) binding protein (CBP). This prevents binding of beta-catenin/CBP...
Molecular Targeted Therapy
Not Required
Colorectal Cancer, Endometrial Cancer, Hepatocellular Cancer, Solid Tumor
22-35
MRT-2359 induces degradation of GSPT1 and associated downregulation of MYC transcription factors and their transcriptional outputs, which may lead to preferential anti-proliferative activity in MYC-driven...
Molecular Targeted Therapy
Not Required
Lung Cancer (NSCLC), Lung Cancer (SCLC), Lymphoma (Diffuse Large B-cell), Solid Tumor
22-23
ART0380 selectively targets and inhibits ATR activity and blocks the downstream phosphorylation of the serine/threonine protein kinase checkpoint kinase 1 (CHK1). This prevents ATR-mediated signaling,...
Molecular Targeted Therapy
Solid Tumor
22-20
PEEL-224 is a small molecule topoisomerase 1 (TOP1) inhibitor, which may lead to inhibiting the repair of single-strand DNA breaks, DNA replication, and tumor cell...
Molecular Targeted Therapy
Not Required
Solid Tumor
22-17
RMC-6236 inhibits the RAS(ON) state of multiple RAS variants both mutant and wild-type proteins.
Molecular Targeted Therapy
KRAS G12
Colorectal Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Solid Tumor
Yes
22-16
BP1001 a liposome-incorporated Grb2 antisense oligodeoxynucleotide binds directly to and blocks Grb2 mRNA, thereby preventing Grb2 protein synthesis, leading to inhibition of cell proliferation of...
Molecular Targeted Therapy
Not Required
Endometrial Cancer, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Solid Tumor
22-13
UCT-03-008, CDK4/6 inhibitor, inhibits protein kinase from working and therefore, potentially stopping cancer cells to grow. Protein kinases are enzymes that are involved in the...
Molecular Targeted Therapy
Solid Tumor
21-41
ASP1570 is a small molecule immuno-oncology agent that is expected to act through the activation of immune cells in the tumor microenvironment.
Molecular Targeted Therapy
Not Required
Lung Cancer (NSCLC), Skin Cancer/ Melanoma, Solid Tumor
Yes
21-29
GS-GS-1811 is a monoclonal antibody that is designed to bind to CCR8. It is thought to target Tumor-Infiltrating T Regulatory cells for depletion by enhancing...
Immunotherapy
Not Required
Breast Cancer, Gastric/GEJ Cancer, Head and Neck Cancer, Lung Cancer (NSCLC), Solid Tumor
21-25
BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion...
Molecular Targeted Therapy
Lung Cancer (NSCLC), Solid Tumor
Yes
20-26
Entrectinib: Inhibitor of the tyrosine kinases TrkA, TrkB, TrkC, ROS1, and ALK Alectinib: ALK kinase inhibitor
Antibody Drug Conjugate, Molecular Targeted Therapy
Yes
Solid Tumor
18-26
MRTX849 is a potent, highly selective and orally available small molecule inhibitor of a form of KRAS that harbors an oncogenic substitution mutation (G12C).
Molecular Targeted Therapy
KRAS G12C
Solid Tumor
Yes
1-JIT-TSC-007
n/a
Molecular Targeted Therapy
Inactivating Alterations in TSC1 or TSC2
Solid Tumor
1-JIT-ENV-ONC-101
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
PTCH1 loss of function
Solid Tumor
1-JIT-20210023
n/a
Immunotherapy, Molecular Targeted Therapy
CDKN2A null, MTAP null
Solid Tumor
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000
